First Horizon National (FHN) Announces Departure of its CFO William Losch

First Horizon Corporation (NYSE: FHN or “First Horizon”) today announced that Chief Financial Officer William “BJ” Losch will be departing effective July 31, 2021, to pursue another opportunity at Live Oak Bancshares. Chief Operating Officer Anthony Restel will serve as interim CFO following Losch’s departure until a permanent successor is named.

“We are incredibly fortunate to have tremendous depth of talent across the combined organization,” said President and CEO Bryan Jordan. ”I am pleased to have Anthony, former IBERIABANK Chief Financial Officer, serve as our CFO on an interim basis while we conduct a thorough search. His expertise and familiarity with our culture and Company will help ensure that we have continued momentum toward integrating our two organizations and achieving our goal of becoming a top-performing regional bank.”

“BJ has made significant contributions to the First Horizon organization over the last 12 years. He has been instrumental in executing our growth strategy through times of great change and unprecedented headwinds. We will miss him, but we wish him well as he starts the next chapter in his career with an opportunity to move back to North Carolina.”

Restel currently serves as Chief Operating Officer for First Horizon, responsible for strategic initiatives, information technology, corporate operations, business transformation and corporate security. He will continue to play an integral role with integration activities. The Merger Project Office will continue to be led by merger executives Randy Bryan and Yousef Valine. Most recently, Restel served as Chief Financial Officer for IBERIABANK from 2006 to July 1, 2020, where he also presided over information technology, deposit operations, business transformation, and corporate security. He also served as IBERIABANK’S Chief Credit Officer from 2006 to 2009.

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab
• Clarivate (CLVT) Acquires Global QMS